CRISPR Infusion Keeps Monkey Blood Fats Low Three Years

One infusion, three years of lower blood fats. Researchers at Verve Therapeutics and collaborating institutions report in Nature that a single CRISPR base-editing treatment kept triglyceride levels low in monkeys for three years, raising the prospect of controlling blood fats with a lasting DNA change instead of daily medication. Verve, an Eli Lilly subsidiary, funded the work.

The treatment disables ANGPTL3, a gene that encodes a liver-secreted protein which slows the clearance of fats from the blood. The researchers packaged RNA instructions for a CRISPR base editor and a guide inside tiny fat-based particles. The guide directs the editor to ANGPTL3, where changing one DNA letter disrupts the instructions for making the protein, and the delivery components clear while the DNA change is designed to remain.

The durability numbers are the core of the paper. Ten monkeys with normal blood lipid levels received one infusion and were followed for three years. ANGPTL3 protein in the group averaged about 94 percent below pretreatment levels, triglycerides averaged 43 percent lower, and LDL cholesterol fell by a more modest 13 percent. Liver samples showed similar levels at seven weeks and at three years.

A second experiment tested the approach where it matters most. In four monkeys whose LDL-receptor gene had been disrupted, modeling the receptor shortage behind homozygous familial hypercholesterolemia, the treatment cut average LDL cholesterol from 458 to 247 milligrams per deciliter after 35 days, a 46 percent drop. The particles carry a sugar-based targeting molecule called GalNAc, which enters liver cells through a different receptor when LDL receptors are scarce. That shorter test didn't establish years of lowering in receptor-deficient animals, and the paper doesn't claim it did.

The safety record so far is narrow and stated plainly. Liver enzymes rose temporarily in the treated monkeys and returned to baseline within two weeks, and follow-up tests and tissue examinations found no evidence of lasting liver toxicity. In cultured human liver cells, the human version produced no detectable unintended editing at roughly 3,000 candidate DNA sites, a targeted search that can't exclude every possible unwanted change.

The human version has a name and a trial. It's called VERVE-201, and it's being evaluated in a phase 1b trial for people whose blood lipids remain inadequately controlled. Most of the paper's authors are Verve employees, and several hold Lilly shares or are named on related patent applications, which the report discloses. Whether a lasting edit can safely replace chronic lipid treatment is now a question for those human trials, not for the monkey data.